The authors are grateful to Åke Blomqvist, Kurt Brännäs, Eva Mörk, Magnus Wikström, two anonymous referees and participants at seminars at Dalarna University, University of Gävle, Umeå University and Uppsala University for comments and suggestions. A research grant from the Swedish Competition Authority is gratefully acknowledged.
Consumer Information and Pharmaceutical Prices: Theory and Evidence*
Article first published online: 23 NOV 2010
© Blackwell Publishing Ltd and the Department of Economics, University of Oxford, 2010
Oxford Bulletin of Economics and Statistics
Volume 73, Issue 2, pages 230–254, April 2011
How to Cite
Granlund, D. and Rudholm, N. (2011), Consumer Information and Pharmaceutical Prices: Theory and Evidence. Oxford Bulletin of Economics and Statistics, 73: 230–254. doi: 10.1111/j.1468-0084.2010.00614.x
- Issue published online: 21 FEB 2011
- Article first published online: 23 NOV 2010
- Final Manuscript Received: August 2010.
The impact of a reform that increased consumer information on brand name and generic pharmaceutical prices is analysed both theoretically and empirically. The theoretical results show that an increase in information likely reduces the price of brand name pharmaceuticals, while the results regarding generics are less clear. In the empirical part of the article, the introduction of the substitution reform in the Swedish pharmaceuticals market in October 2002 is used as a natural experiment regarding the effects of increased consumer information. The results clearly show that the reform has lowered the price of both brand name and generic pharmaceuticals.